Novavax plans to trial combined flu and COVID super jab in Australia

Novavax is yet to confirm when it expects to complete applications to get its coronavirus vaccine approved in Australia, but the biotech is already planning new local research into a combined influenza and COVID-19 shot. The vaccine developer has again pushed out timelines for the approval of its vaccines in the US. It told investors on an earnings call overnight it now expects to file for emergency use approval with the Food and Drug Administration during the last three months of this year. Novavax won a $US1.75 billion contract to develop its vaccine for the US market but its quarterly report revealed on Thursday the federal government may withhold funding until the company can resolve concerns about its processes.